PDE5 Inhibitors: How to Pick the Right Agent for Each Patient

What Is the PDE5 Inhibitor Drug Class?

PDE5 inhibitors block phosphodiesterase type 5, the enzyme that breaks down cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. When cGMP accumulates, smooth muscle relaxes and blood vessels dilate. In penile tissue, that means increased arterial inflow and erection. In the pulmonary vasculature, it means reduced right-heart afterload.

Sexual stimulation must still trigger nitric oxide release for the drugs to work. PDE5 inhibitors amplify the signal; they do not replace it. That single fact explains why they fail in men with severe autonomic neuropathy, radical prostatectomy with complete nerve resection, or testosterone deficiency that has not been corrected.

Shared Pharmacology

All four agents are competitive, reversible PDE5 inhibitors. Selectivity over PDE6 (retina) and PDE11 (testes, skeletal muscle) differs by agent and partly explains their adverse-effect profiles. Sildenafil has the lowest PDE5/PDE6 selectivity ratio, which accounts for transient blue-tinged vision at higher doses [1].

cGMP Pathway and Clinical Relevance

Nitric oxide activates guanylate cyclase, producing cGMP. CGMP activates protein kinase G, which phosphorylates myosin light-chain kinase and opens potassium channels, causing smooth-muscle relaxation. PDE5 terminates that signal. Blocking PDE5 therefore potentiates any source of nitric oxide, including exogenous nitrates. That overlap is why nitrate co-administration causes catastrophic hypotension and remains an absolute contraindication across every agent in the class [2].

Sildenafil (Viagra / Revatio): The Reference Standard

Sildenafil was the first oral PDE5 inhibitor approved by the FDA, cleared for erectile dysfunction in March 1998 and for pulmonary arterial hypertension (PAH) under the brand Revatio in 2005 [3].

Pharmacokinetics

Sildenafil reaches peak plasma concentration in 30 to 120 minutes. A high-fat meal delays Tmax by about 60 minutes and reduces Cmax by 29%, a clinically meaningful reduction that shifts the functional onset window [4]. The half-life is 3 to 5 hours. CYP3A4 is the primary metabolic pathway; CYP2C9 contributes a minor route.

Dosing for ED

The starting dose is 50 mg taken 30 to 60 minutes before anticipated activity. Doses range from 25 mg (CYP3A4 inhibitors, hepatic impairment, age over 65) to 100 mg. Patients should not exceed one dose per 24 hours. The prescriber note from the FDA label states: "Sildenafil has no effect in the absence of sexual stimulation" [3].

Dosing for PAH

Revatio is dosed at 20 mg three times daily, approximately 4 to 6 hours apart. The SUPER-1 trial (N=278) showed that sildenafil 20, 40, and 80 mg TID each improved six-minute walk distance versus placebo at 12 weeks, with 20 mg producing a 45-meter improvement (P<0.001) [5]. Only the 20 mg TID dose is FDA-approved for PAH.

When to Choose Sildenafil

Sildenafil is the best-studied agent in the class. Choose it when cost is the dominant concern (generic sildenafil costs under $1 per tablet at most pharmacies), when PAH is the indication, or when the patient's sexual activity is predictable and occurs at least 30 minutes after a light meal.

Tadalafil (Cialis / Adcirca): The Versatile Daily Agent

Tadalafil's half-life of approximately 17.5 hours produces a pharmacologically active window of up to 36 hours, which is why it earned the marketing description "the weekend pill." That long duration is not merely a commercial point. It changes how patients plan intimacy and substantially improves treatment satisfaction in randomized data [6].

Indications: ED, BPH, and PAH

Tadalafil is the only PDE5 inhibitor approved for all three indications: ED, benign prostatic hyperplasia, and PAH (as Adcirca, 40 mg once daily). For ED plus BPH, tadalafil 5 mg daily is the only agent with dual FDA labeling, making it the rational default when a man presents with both conditions [7].

Pharmacokinetics

Food does not significantly affect tadalafil absorption, a practical advantage over sildenafil and vardenafil. Steady-state plasma levels on daily 5 mg dosing are reached within five days. CYP3A4 handles primary metabolism. No active circulating metabolites have been identified.

Dosing Options

• On-demand ED: 10 mg taken at least 30 minutes before activity; titrate to 20 mg or down to 5 mg based on response and tolerability.
• Daily ED: 2.5 mg once daily, titrate to 5 mg.
• ED + BPH: 5 mg once daily.
• PAH (Adcirca): 40 mg once daily.

When to Choose Tadalafil

Daily tadalafil suits men who prefer spontaneous sexual activity, men with BPH-related lower urinary tract symptoms, and men in whom psychogenic performance anxiety is partly driving their ED. The Cialis STEP trial showed that daily tadalafil 5 mg significantly improved International Index of Erectile Function (IIEF) domain scores versus placebo over 12 weeks (mean improvement 6.4 vs. 1.2 points, P<0.001) [8].

Vardenafil (Levitra / Staxyn): Potency and the Meal Caveat

Vardenafil has a higher binding affinity for PDE5 than sildenafil on a molar basis, though that biochemical fact does not reliably translate to greater clinical efficacy in head-to-head trials [9]. Its half-life is 4 to 5 hours, comparable to sildenafil.

Pharmacokinetics

A high-fat meal reduces vardenafil Cmax by approximately 35% and delays Tmax. Like sildenafil, vardenafil should be taken on an empty stomach or after a low-fat meal for predictable onset. The orally disintegrating tablet formulation (Staxyn, 10 mg) has different bioavailability than conventional vardenafil and is not interchangeable on a milligram-per-milligram basis.

QTc Prolongation Signal

Vardenafil carries an FDA-required warning about QTc prolongation, a class effect that is more pronounced with vardenafil than with sildenafil or tadalafil [10]. Avoid combining it with Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol).

Dosing for ED

Standard starting dose is 10 mg taken 25 to 60 minutes before activity. Dose range: 5 to 20 mg, maximum once per 24 hours. Reduce to 5 mg in men over 65 or with moderate hepatic impairment (Child-Pugh B).

When to Choose Vardenafil

Vardenafil offers a modest additional option for men who have not responded well to sildenafil at equivalent doses, though switching within the class produces inconsistent results in clinical practice. Some prescribers prefer it for men with mild-to-moderate hepatic dysfunction when tadalafil is less desirable, because vardenafil's shorter half-life limits drug accumulation.

Avanafil (Stendra): Speed as the Differentiator

Avanafil was FDA-approved in 2012 and is the newest agent in the class [11]. Its principal differentiator is onset speed.

Pharmacokinetics

Avanafil reaches peak plasma concentration in approximately 30 to 45 minutes, and clinical trial data support meaningful efficacy at 15 minutes post-dose in some patients. The half-life is 3 to 5 hours. Food does not substantially affect absorption, giving avanafil the same meal-independence advantage as tadalafil.

Selectivity Profile

Avanafil has greater selectivity for PDE5 over PDE6 and PDE11 compared to sildenafil and vardenafil [12]. The practical implication is a lower rate of visual disturbance and back pain/myalgia in post-marketing experience, though direct head-to-head safety trials are limited.

Dosing for ED

Starting dose is 100 mg taken approximately 15 minutes before anticipated activity. Dose range: 50 to 200 mg once per 24 hours. The 50 mg dose is available for CYP3A4 inhibitor co-administration.

ENDURE Trial Data

The ENDURE trial (N=646) showed that avanafil 100 mg and 200 mg significantly improved IIEF erectile function domain scores versus placebo at 12 weeks. At 15 minutes post-dose, 64% of avanafil 200 mg attempts were successful versus 27% placebo (P<0.001) [13].

When to Choose Avanafil

Choose avanafil when the patient specifically wants the shortest possible onset window, when spontaneity is the primary concern, and when cost is not prohibitive (avanafil remains brand-only as of early 2025 and carries a higher out-of-pocket cost than generic sildenafil or tadalafil).

Head-to-Head Comparison: Pharmacokinetic and Clinical Summary

The table below consolidates the prescribing decision variables most relevant in clinical practice.

| Parameter | Sildenafil | Tadalafil | Vardenafil | Avanafil | |---|---|---|---|---| | FDA approval (ED) | 1998 | 2003 | 2003 | 2012 | | Half-life | 3 to 5 h | ~17.5 h | 4 to 5 h | 3 to 5 h | | Time to Cmax | 30 to 120 min | 2 h | 30 to 120 min | 30 to 45 min | | Food effect | Yes (high-fat) | No | Yes (high-fat) | No | | Daily ED dosing | No | Yes (2.5 to 5 mg) | No | No | | BPH indication | No | Yes | No | No | | PAH indication | Yes | Yes | No | No | | QTc concern | Low | Low | Moderate | Low | | Generic available | Yes | Yes | Yes | No | | On-demand ED dose range | 25 to 100 mg | 5 to 20 mg | 5 to 20 mg | 50 to 200 mg |

Drug Interactions Across the Class

Every PDE5 inhibitor shares two interaction categories that demand attention before prescribing.

Nitrates: Absolute Contraindication

Organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and nitric-oxide donors (amyl nitrite, inhaled recreational nitrites) are absolutely contraindicated with all PDE5 inhibitors. The combination produces additive vasodilation and can cause severe, refractory hypotension. The 2018 ACC/AHA guideline on stable ischemic heart disease states: "The combination of a PDE5 inhibitor with a nitrate is contraindicated regardless of route or formulation of nitrate" [14].

A practical time buffer applies when switching. After the last sildenafil, vardenafil, or avanafil dose, wait at least 24 hours before administering a nitrate. After tadalafil, the required washout is at least 48 hours, reflecting its longer half-life.

Alpha-Blockers: Additive Hypotension

Alpha-1 blockers (tamsulosin, doxazosin, terazosin) lower blood pressure independently and can cause additive hypotension with PDE5 inhibitors. Tamsulosin at 0.4 mg daily has the most favorable interaction data and is considered relatively compatible with tadalafil 5 mg daily in men taking both for BPH and ED. Doxazosin and non-uroselective alpha-blockers carry higher risk for orthostatic hypotension and should be used with caution, initiating PDE5 inhibitor therapy at the lowest dose after the patient is stabilized on the alpha-blocker [2].

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase plasma concentrations of all four agents. Dose reductions are required. Ritonavir-based HIV regimens require sildenafil doses no greater than 25 mg per 48 hours; tadalafil doses no greater than 10 mg per 72 hours [3].

Special Populations

Cardiovascular Disease

PDE5 inhibitors produce modest systemic blood pressure reductions (mean 8 to 10 mmHg systolic in clinical trials). Most men with stable cardiovascular disease can use them safely. The Princeton III Consensus statement classifies cardiovascular risk into low, intermediate, and high categories and provides prescribing guidance accordingly [15]. High-risk patients (unstable angina, uncontrolled hypertension, recent MI within 90 days, NYHA Class III/IV heart failure) should defer sexual activity and PDE5 inhibitor use until risk is reassessed.

Renal Impairment

Sildenafil AUC increases approximately 100% in severe renal impairment (creatinine clearance <30 mL/min); start at 25 mg. Tadalafil on-demand: maximum 10 mg every 48 hours for creatinine clearance <30 mL/min; daily dosing is not recommended. Vardenafil requires no adjustment for mild-to-moderate renal impairment but use caution with severe impairment. Avanafil: data in severe renal impairment are insufficient; avoid or use the lowest dose.

Hepatic Impairment

Child-Pugh A: no dose adjustment required for any agent. Child-Pugh B: reduce sildenafil to 25 mg starting dose; tadalafil to maximum 10 mg on-demand; vardenafil to 5 mg. Child-Pugh C: all four agents are contraindicated or use is unsupported by safety data.

Older Adults

Age over 65 is associated with reduced CYP3A4 activity and lower drug clearance. Start at the lowest approved dose for each agent. The FDA label for sildenafil specifically recommends a 25 mg starting dose for men over 65 [3].

Pulmonary Arterial Hypertension: Choosing Between Sildenafil and Tadalafil

For PAH, the choice narrows to sildenafil (Revatio) and tadalafil (Adcirca). Riociguat, a soluble guanylate cyclase stimulator, is contraindicated with PDE5 inhibitors and must never be co-prescribed.

Sildenafil in PAH

Sildenafil 20 mg TID is the approved regimen. The SUPER-1 trial demonstrated a 45-meter improvement in six-minute walk distance at 12 weeks (P<0.001) [5]. Three-times-daily dosing is a compliance burden for some patients.

Tadalafil in PAH

The PHIRST trial (N=405) tested tadalafil 2.5, 10, 20, and 40 mg once daily versus placebo in PAH patients, approximately half of whom were on background bosentan therapy. Tadalafil 40 mg produced a 33-meter improvement in six-minute walk distance versus placebo at 16 weeks (P=0.003), along with reduced time to clinical worsening [16]. Once-daily dosing supports adherence.

Selecting Between the Two for PAH

Once-daily tadalafil 40 mg is favored when adherence is a concern or when the patient is already using tadalafil for ED. Sildenafil is preferred when IV-to-oral transition is required (IV sildenafil is available outside the US for acute inpatient management). Prescribers should consult the most recent Pulmonary Hypertension Association clinical guidelines for combination therapy decision trees [17].

Practical Prescribing Decision Framework

The following four questions guide agent selection in under two minutes at the point of prescribing.

1. Does the patient have BPH with bothersome lower urinary tract symptoms? Yes: tadalafil 5 mg daily is the only agent with dual FDA labeling. Stop here.

2. Is spontaneity the primary concern and is the patient willing to pay brand pricing? Yes: avanafil 100 mg on-demand. Consider tadalafil daily as an alternative if cost is negotiable.

3. Is cost the limiting factor? Yes: generic sildenafil 50 mg on-demand is the first-line choice. Generic tadalafil daily is an alternative.

4. Does the patient have PAH? Yes: tadalafil 40 mg daily (once-daily adherence advantage) or sildenafil 20 mg TID. Check for riociguat and nitrate co-prescriptions before dispensing.

If none of the above applies, sildenafil 50 mg on-demand remains the most-studied default with the most extensive long-term safety data in the class.

Adverse Effects: What Differs by Agent

Shared class effects include headache (10 to 16%), flushing (10 to 12%), nasal congestion, and dyspepsia. Three effects differ meaningfully across agents.

Visual disturbance (blue-tinged vision, photosensitivity): Sildenafil has the highest rate due to lower PDE6 selectivity. Avanafil has the lowest rate. Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely with all agents; risk is higher with pre-existing optic disc anomaly or prior NAION [2].

Back pain and myalgia: Most common with tadalafil (reported in approximately 6% of users in clinical trials), attributed to PDE11 inhibition in skeletal muscle. Generally resolves within 48 hours without intervention.

Hearing loss: Sudden sensorineural hearing loss has been reported post-marketing with all PDE5 inhibitors. The FDA added a warning to all labels in 2007 [10]. Instruct patients to stop the drug and seek evaluation immediately if sudden hearing loss occurs.